The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections
Abstract
The pharmacokinetics and pharmacodynamics of linezolid have been extensively investigated in laboratory models, healthy volunteers and patients. Three formulations exist: an intravenous (iv) form, film-coated tablets and an oral suspension. Linezolid can be assayed in serum and body fluids by HPLC and has good bioavailability with a Cmax at 0.5-2 h. The protein binding is 31%, and the volume of distribution is 30-50 L with adequate to good tissue penetration into skin blister fluids, bone, muscle, fat, alveolar cells, lung extracellular lining fluid and CSF. There are two major metabolites of linezolid (PNU-142586 and PNU-142300). Non-enzymic formation of PNU-142586 is the rate-limiting step in the clearance of linezolid, and linezolid and its two main metabolites plus several minor ones are all excreted in the urine. Dose linearity is evident in the Cmax and AUC across a wide range of doses. Gender and age have little effect on pharmacokinetics, but children have greater plasma clearance and volume of distribution and hence, have lower serum concentrations for equivalent doses in adults. No dose modification is needed in mild to moderate liver disease or any degree of renal impairment; however, both PNU-142586 and PNU-142300 accumulate in renal failure. Linezolid is bacteriostatic with a significant post-antibiotic effect against the key pathogens. In animal models of infection, the time the antibiotic concentration exceeds the MIC (t > MIC) helps to determine outcome, and a t > MIC of 40% is predictive of a bacteriostatic effect for both staphylococci and pneumococci. In man, t > MIC and AUC/MIC have been related to bacteriological and clinical outcomes. AUC and length of treatment are also related to the risk of thrombocytopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections
Perry, C. M., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161040-00008 · Cited by 275
Slatter, J. G., Stalker, D. J., Feenstra, K. L., Welshman, I. R., BRUSS, J. B., Sams, J. P., Johnson, M. G., Sanders, P., Hauer, M. J., Fagerness, P. E., et al. (2001) · PubMed · Cited by 248
Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral Doses
Gee, T., Ellis, R., Marshall, G., Andrews, J., Ashby, J., & Wise, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1843-1846.2001 · Cited by 220
Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests
MacGowan, A. P., & Wise, R. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.suppl_1.17 · Cited by 187
Self-citationThe in-vitro activity of linezolid (U-100766) and tentative breakpoints
Wise, R. A., Andrews, J. M., Boswell, F. J., & Ashby, J. P. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.6.721 · Cited by 149
Rybak, M. J., Cappelletty, D. M., Moldovan, T., Aeschlimann, J. R., & Kaatz, G. W. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.721 · Cited by 147
Hendershot, P. E., Antal, E. J., Welshman, I. R., Batts, D. H., & Hopkins, N. K. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010302 · Cited by 86
Antal, E. J., Hendershot, P. E., Batts, D. H., Sheu, W.-P., Hopkins, N. K., & Donaldson, K. M. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010294 · Cited by 69
A Pharmacokinetic Evaluation of Concomitant Administration of Linezolid and Aztreonam
Sisson, T. L., Jungbluth, G. L., & Hopkins, N. K. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922011962 · Cited by 47
Cited by
Mitochondrial Cardiolipin Is Required for Nlrp3 Inflammasome Activation
Iyer, S. S., He, Q., Janczy, J. R., Elliott, E. I., Zhong, Z., Olivier, A. K., Sadler, J. J., Knepper-Adrian, V., Han, R., Qiao, L., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.001 · Cited by 931
Pharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Hanley, M. J., Abernethy, D. R., & Greenblatt, D. J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318100-000000000-00000 · Cited by 773
Linezolid: a review of its properties, function, and use in critical care
Hashemian, S. M., Farhadi, T., & Ganjparvar, M. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s164515 · Cited by 459
Steinkraus, G., White, R., & Friedrich, L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm258 · Cited by 420
Augmented Renal Clearance: Implications for Antibacterial Dosing in the Critically Ill
Udy, A. A., Roberts, J. A., Boots, R. J., Paterson, D. L., & Lipman, J. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318140-000000000-00000 · Cited by 377
Cheng, V. C. C., Lau, Y.-K., Lee, K.-L., Yiu, K.-H., Chan, K.-H., Ho, P.-L., & Yuen, K.-Y. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.08.021 · Cited by 32
Metadata
- Authors
- MacGowan, A. P.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-05-01
- Volume
- 51
- Issue
- 90002
- Pages
- 17ii-25
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2161181970
- Cited by
- 299
- References
- 9
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.